Entering text into the input field will update the search result below

Forma Therapeutics jumps 48% on $1.1B buyout deal with Novo Nordisk

Sep. 01, 2022 8:38 AM ETNovo Nordisk A/S (NVO)NONOFBy: Dulan Lokuwithana, SA News Editor6 Comments

word m and a made with wood building blocks, stock image

Maksim Labkouski

Danish drugmaker Novo Nordisk A/S (NVO) (OTCPK:NONOF) has agreed to acquire Forma Therapeutics (FMTX), a U.S.-based biotech focused on therapies for sickle cell disease (SCD), in an all-cash deal worth $1.1B in equity value, the companies

Recommended For You

Comments (6)

Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

All bio sector underwater with deep value everywhere... you need a bucket!
Tobias_Funke profile picture
Should have bought GBT last year instead of allowing Pfizer to grab it recently. Not sure about Forma as they have been around for a while. They have some oncology assets so who knows. NVO is a good company so I have faith.
Sage Advisors profile picture
@Tobias_Funke Gene therapies are likely to take a large piece of the market and surely the most severe cases of sickle cell.
Tobias_Funke profile picture
@Sage Advisors maybe....we will see.
Forma's IPO and secondary raises were at $2B valuation.
More than 50% loss for majority of investors.
Sage Advisors profile picture
Im not sure what SICK cell is...SICKLE cell???
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.